PATENT CLAIM ANALYSIS

Application Number: 15749322
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["514", "299000"]

Abstract:
Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Claim (Index 1):
A compound having the Formula I: or a pharmaceutically acceptable salt thereof, wherein\n X is \u2014C(O)NH\u2014 or \u2014NHC(O)\u2014; \n A is CH or N; \n Y is CR 10  or N; \n n is 0, 1, 2, or 3; \n p is 0, 1, or 2; \n L 2  is CH 2 , CH 2 CH 2 , CHMe, O, C(\u2550O), CH(OH), or CH 2 O, where the oxygen atom in CH 2 O can either be attached to Cy 2  or to the carbon atom on the center ring bridging NR 2  and A; \n L 1  is absent or is CR 7 R 8 ; \n Cy 1  is selected from aryl, heteroaryl, heterocyclyl, and cycloalkyl, wherein the aryl, heteroaryl, heterocyclyl, and cycloalkyl are each substituted with 1 to 3 groups independently selected from R 5 ; \n Cy 2  is selected from aryl, heteroaryl, monocyclic cycloalkyl, and monocyclic heterocyclyl, wherein the aryl, heteroaryl, monocyclic cycloalkyl, and monocyclic heterocyclyl are each optionally substituted with 1 to 3 groups independently selected from R 6 ; \n R 2  is (C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, (C 1 -C 4 )haloalkyl, or monocyclic cycloalkyl; \n R 5  and R 6  are each independently selected from halogen, \u2014CN, \u2014OR c , \u2014NR d R e , \u2014S(O) k R c , \u2014NR c S(O) 2 R c , \u2014S(O) 2 NR d R e , \u2014C(\u2550O)OR c , \u2014OC(\u2550O)OR c , \u2014OC(\u2550O)R c , \u2014OC(\u2550S)OR c , \u2014C(\u2550S)OR c , \u2014OC(\u2550S)R c , \u2014C(\u2550O)NR d R e , \u2014NR c C(\u2550O)R c , \u2014C(\u2550S)NR d R e , \u2014NR c C(\u2550S)R c , \u2014NR c C(\u2550O)OR c , \u2014OC(\u2550O)NR d R e , \u2014NR c (C\u2550S)OR c , \u2014OC(\u2550S)NR d R e , \u2014NR c C(\u2550O)NR d R e , \u2014NR c (C\u2550S)NR d R e , \u2014C(\u2550S)R c , \u2014C(\u2550O)R c , (C 1 -C 6 )alkyl, cycloalkyl, \u2014(CH 2 ) 1-4 -cycloalkyl, heterocyclyl, \u2014(CH 2 ) 1-4 -heterocyclyl, aryl, \u2014NHC(\u2550O)-heterocyclyl, \u2014NHC(\u2550O)-cycloalkyl, \u2014(CH 2 ) 1-4 -aryl, heteroaryl and \u2014(CH 2 ) 1-4 -heteroaryl, \n wherein the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl portion present in each of said (C 1 -C 6 )alkyl, cycloalkyl, \u2014(CH 2 ) 1-4 -cycloalkyl, heterocyclyl, \u2014(CH 2 ) 1-4 -heterocyclyl, aryl, \u2014(CH 2 ) 1-4 -aryl, heteroaryl and \u2014(CH 2 ) 1-4 -heteroaryl substituent for R 6  are further optionally substituted with halogen, OR c , \u2014NO 2 , \u2014CN, \u2014NR c C(\u2550O)R c , \u2014NR d R e , \u2014S(O) k R c , \u2014C(\u2550O)OR c , \u2014C(\u2550O)NR d R e , \u2014C(\u2550O)R c , (C 1 -C 3 )alkyl, halo(C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy(C 1 -C 3 )alkyl, (C 1 -C 3 )alkoxy, or halo(C 1 -C 3 )alkoxy; \n each R c  is independently selected from hydrogen and (C 1 -C 6 )alkyl optionally substituted with 1 to 3 halogen; \n each R d  and R e  is independently selected from hydrogen and (C 1 -C 6 )alkyl; \n k is 0, 1 or 2; \n any heterocyclyl or heteroaryl portion of Cy 1  or Cy 2  is further optionally substituted with \u2550O; \n R 7  and R 8  are each independently hydrogen, OH, (C 1 -C 3 )alkyl, hydroxy(C 1 -C 3 )alkyl, \u2014O(C 1 -C 3 )alkyl, \u2014(C 1 -C 3 )alkyl-O\u2014(C 1 -C 3 )alkyl, \u2014(C 1 -C 3 )alkyl-NH 2 , \u2014(C 1 -C 3 )alkyl-N-di(C 1 -C 3 )alkyl, CO 2 H, (CH 2 ) 1-3 COOH, monocyclic heterocyclyl, \u2014CO\u2014(C 1 -C 3 )alkoxy, \u2014(C 1 -C 3 )alkoxy-C(O)\u2014NH 2 , \u2014(C 1 -C 3 )alkyl-O\u2014(C 1 -C 3 )alkyl-C(O)\u2014NH 2 , \u2014(C 1 -C 3 )alkyl-C(O)\u2014(C 1 -C 3 )alkoxy, \u2014(C 1 -C 3 )alkyl-C(O)\u2014NH 2 , halophenyl, \u2014(C 1 -C 3 )alkyl-halophenyl, or quinolin-2(1H)one-4yl-methyl; \n R 9  is independently (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )alkoxy, or halogen; and \n R 10  is hydrogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )haloalkyl, (C 1 -C 4 )alkoxy, or halogen; \n provided that: \n when A is N, Y is CR 10 , R 10  is hydrogen, R 2  is cyclohexyl, L 2  is CH 2 , Cy 2  is phenyl, X is \u2014C(O)NH, n is 0, p is 0, L 1  is CR 7 R 8 , and one of R 7  or R 8  is COOH and the other is hydrogen, then Cy 1  is not 1H-indol-5-ol-3yl; \n when A is N, Y is CR 10 , R 10  is hydrogen, R 2  is (C 1 -C 4 )alkyl, X is \u2014NHC(O), L 2  is CH 2 , p is 0, n is 0, L 1  is CR 7 R 8 , and both of R 7  and R 8  are hydrogen, then Cy 1  is not piperidinyl; and \n when A is N, Y is CR 10 , R 10  is hydrogen, R 2  is methyl, Cy 1  is aryl, L 2  is CH 2 , p is 0, X is \u2014C(O)NH, n is 0, L 1  is CR 7 R 8 , and both of R 7  or R 8  are hydrogen, then Cy 2  is not phenyl substituted with CN.

Metadata:
- Claim Count in Document: 33.0
- Percentile: 86.0
- Lexical Diversity: 1.54762
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14933468', '15455481', '14990430', '14609798', '14888129']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8742602996989715
- 35 USC 102 Novelty (BERT): 0.5639046312517241
- Combined Prediction Score: 0.8432247328542467
- Mean Citation Score: 451.417868
- Max Citation Score: 455.46802
- Similarity Product: 296.5435178647208

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test